Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →The bearish move named in the October 1, 2026 Investor’s Business Daily listing is a bear call spread on Moderna (NASDAQ: MRNA), based on the possibility of profit-taking after a sharp rally and limited near-term upside. The available listing does not disclose the spread’s strikes, expiration, credit, or maximum loss, so it is not enough to evaluate or reproduce a specific trade. The listing identifies the strategy and thesis, not a complete trade plan.
Why the bearish idea surfaced
A September 30, 2026 Dow Jones report said Citi analyst Geoff Meacham downgraded Moderna from Hold to Sell after a sharp rally following Moderna and Merck’s update to investors on intismeran autogene, their cancer-vaccine candidate. Meacham raised his price target at the same time, from $60 to $80. His concern was that the share price reflected overly optimistic assumptions about success across multiple tumor types and the resulting sales potential; that is his valuation judgment, not an established conclusion about the company’s prospects. Dow Jones report republished by Tiger Brokers.
Dow Jones reported that Moderna had risen nearly 590% year to date heading into the Wednesday session, compared with a 12% gain for the S&P 500. It also reported a 5.7% premarket decline in Moderna shares to $191.96 on Wednesday. These are figures reported at the time, not current market data or independent estimates. The same report cited a FactSet snapshot of 19 firms, excluding Citi: six Buy, 11 Hold, and two Sell or equivalent. That snapshot is not a current consensus.
Meacham’s stated rationale was that “While intismeran could become a market leading therapy in melanoma, we believe the re-rating now reflects successful expansion in many tumor types and unrealistic implied sales,” as quoted by Dow Jones on September 30, 2026. The distinction matters: the bearish case described in the report is primarily about what investors may already expect from the oncology program, not proof that the candidate cannot succeed.
#1 Best Overall
What a bear call spread means here
A bear call spread is an options position built from two call options with the same expiration: the trader sells a call at a lower strike and buys a call at a higher strike. The short call brings in premium; the long call limits the position’s risk if the stock rises sharply. The usual objective is for the stock to finish at or below the lower strike at expiration, allowing both calls to expire without value or leaving some of the credit intact.
This is different from short-selling shares and from selling a call without a hedge. It is a defined-risk position, but “defined” does not mean low risk: the maximum loss can be substantial relative to the credit received, depending on the distance between strikes and the net premium. For a standard one-contract spread on 100 shares, before fees and any early exercise or assignment complications:
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
- Maximum profit: the net credit received when opening the spread.
- Maximum loss: the difference between the strikes, multiplied by 100, minus the net credit.
- Expiration breakeven: the lower strike plus the net credit per share.
Those formulas explain the mechanics only; they do not supply the missing terms of the IBD trade. Without its actual strikes, expiration, and credit, no reader can calculate that trade’s breakeven, potential return, or maximum loss.
What the available listing does—and does not—establish
The Muck Rack listing for Gavin McMaster’s October 1, 2026 IBD article describes a bear call spread and a thesis of possible profit-taking after Moderna’s rally. It does not reveal the option legs or establish that the setup remains available or appropriate now. A strategy label and a market opinion are not a complete recommendation: options prices, expiration dates, implied volatility, and the stock price change continuously.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Before considering any bearish options position, a reader would need, at minimum, the exact strikes and expiration, the net credit at entry, the spread width, the resulting maximum loss and breakeven, and the assumptions about the stock at expiration. The potential for a favorable cancer-vaccine update or a broader market move higher also matters: either could push the shares above the short-call strike. A defined-risk structure caps loss at expiration under its stated terms, but does not remove the possibility of losing the full maximum amount.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Why the clinical evidence remains important
The Dow Jones report said the latest trial met its main goal, but the coverage did not disclose detailed results. It identified the European Society for Medical Oncology meeting in late October 2026 as a possible venue for further detail. The report attributed two interpretive thresholds to Meacham: a recurrence-free-survival hazard ratio around 0.72 as “clinical credible,” and 0.65 or lower as “a clear win.” These are the analyst’s stated judgments, not clinical standards or regulator-set cutoffs.
Rank #4
Without detailed trial figures in that report, its clinical account cannot settle how meaningful the result is, how broadly it may apply, or how much commercial opportunity the candidate could have. Readers should distinguish those unresolved questions from the separate claim that the stock’s valuation already assumes too much.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
How to judge the bearish thesis without turning it into a trade signal
- Separate the business question from the options question. Whether expectations are too high is a view about Moderna’s valuation and prospects. Whether a particular spread offers an acceptable risk-reward depends on its terms and market pricing.
- Check what new evidence could change the thesis. Detailed clinical results, especially information on the trial’s outcomes and their context, could alter expectations in either direction.
- Compare the risk with the credit. A spread’s maximum loss, breakeven, time to expiration, and sensitivity to volatility cannot be inferred from the strategy name.
- Treat dated market figures as historical. The reported rally, premarket price, and analyst-rating snapshot describe September 2026, not the present market or present analyst views.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minute
